8-K filing — Design Therapeutics, Inc. (DSGN)
Filed: 2026-08-03 AccNo: 0001193125-26-329570 Size: 489 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Design Therapeutics Q2 EPS $(0.32) Beats $(0.34) Estimate
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 5.88 percent increase over losses of $(0.34) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 12:04 PM
- Checked
- Aug 3, 2026, 12:04 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading